Who doesn't love a "Blues’ Shuffle?"

Is the steady flow of leaders from one Blue plan to another, the "Blues’ Shuffle", ultimately good or bad for plans, members, and the brand?

Context. In the past 12 months, multiple Blue Board members have reached out to me to express concern about losing top executives to other Blue plans; recent appointments suggest the musical chairs cycle has resumed.

Executive Summary

The Blues system regularly sees executives, CEOs, EVPs, SVPs, and VPs, move between plans. We document recent, publicly reported moves and assess systemic pros and cons.

Upside: faster diffusion of best practices, cultural compatibility, lower ramp time, and a deeper, system wide bench.

Downside: familiarity over innovation, talent drain for source plans, inflationary compensation pressure, succession gaps, potential groupthink, and optics that may unsettle regulators, partners, and employees.

Deeper question:

Does this recycling of talent ensure stability, or does it entrench insularity and inhibit genuine transformation?

We offer 10 board ready actions to reduce risk while preserving the benefits of an integrated leadership market across Blues.

Defining the "Blues’ Shuffle"

Executives and senior leaders (CEO, COO, CFO, CIO/CTO, CMO, plus EVP/SVP/VP roles) leaving one Blue plan or Blue enterprise subsidiary to join another Blue plan or a Blue enterprise subsidiary in a new role.

Typical pathways

Plan to Plan: examples include market presidents, finance, provider network leadership.

Enterprise to Subsidiary (or vice versa): moves within diversified Blue groups such as Florida Blue/GuideWell to Triple S Management.

Function to function: IT/data, clinical, operations, finance, government programs, HR/talent.

Why it happens (drivers)

Proven fit with Blue culture and governance. Familiarity with BCBSA rules, naming and brand standards, and BlueCard mechanics lowers execution risk.

Scale and specialization. Larger plans recruit niche expertise in MA growth, drug benefit redesign, analytics, and care model transformation.

Change cycles. Post pandemic restructurings, pharmacy model shifts, MA headwinds, and regional consolidations open high impact roles.

Remote and hybrid elasticity. Wider search footprints make cross market moves easier.

Reputation arbitrage. Top talent chases higher visibility turnarounds or innovation agendas.

What’s good about a Blues’ Shuffle?

Cross pollination of playbooks. Proven programs such as value based care constructs, member experience operations, and network strategies travel faster.

Shorter ramp times. Leaders already fluent in BlueCard, association policies, and plan economics can execute sooner.

System bench strength. The broader Blue ecosystem benefits when seasoned leaders tackle the hardest problems where they are most needed.

Credibility with stakeholders. Provider systems, regulators, and employers recognize a familiar brand and operating model.

What’s bad about a Blues’ Shuffle?

Local brain drain. Source plans lose market specific relationships and tacit knowledge such as hospital negotiations and political context.

Inflationary pressure on compensation. Bidding wars raise fixed costs.

Execution dips during transition. Backfills and interim periods risk missed P&L targets and quality or service slippage.

Optics and morale. Frequent departures can signal instability or a stepping stone culture.

Concentration risk and groupthink. Over reliance on a shared set of Blue veterans can narrow the idea pipeline.

Questionable innovation yield. Recycling the same leadership cadre risks perpetuating the same strategies. While safe and familiar, boards must ask: will recycled Blue executives ever be true change agents who drive transformation, or are they conditioned to defend legacy structures?

The innovation dilemma

Blue plans have rarely been accused of setting the world on fire - or being particularly innovative, for that matter. But, they face mounting external pressures including CMS audits, MA payment headwinds, drug benefit costs, and digital first competitors. If leadership selection is limited to the same revolving set of executives, then the very attributes that ensure stability, cultural fluency, and system trust, may also blunt disruptive potential. In other words, the Blues’ Shuffle may unintentionally cement incrementalism rather than enable breakthrough innovation.

Key questions for boards:

Are we valuing cultural safety over strategic risk taking?

Does our executive slate reflect diverse experience such as payer, provider, tech, consumer, or mainly internal Blue pathways?

How do we import fresh DNA without destabilizing governance?

Field evidence (illustrative recent moves)

Selected senior moves across roles and functions; examples include CEOs, EVPs, SVPs, and VPs.

CareFirst to GuideWell/Florida Blue (CEO)

Blue Shield of California to Blue Cross Blue Shield of Massachusetts (CEO)

BCBS Minnesota to Florida Blue (CEO); earlier Horizon BCBSNJ to BCBS Minnesota (SVP to CEO)

CareFirst to Blue Cross Blue Shield of Massachusetts (EVP/CFO)

Florida Blue/GuideWell to Triple S Management (CEO)

Excellus BCBS to Highmark Health (SVP)

BCBS Minnesota to Highmark Health (Enterprise CIO)

HCSC (BCBS IL/TX/OK/NM/MT) to Blue Shield of California (SVP)

Capital Blue Cross to Horizon BCBS of New Jersey (SVP)

BCBS Illinois to Premera Blue Cross (SVP)

Kim Keck, BCBS Rhode Island CEO to President and CEO of Blue Cross Blue Shield Association

Martha L. Wofford succeeding Keck as CEO of BCBS Rhode Island (moved from DaVita and Aetna leadership)

Gary D. St. Hilaire, Capital Blue Cross CEO to Horizon BCBS of New Jersey CEO

Bryan Camerlinck, Blue KC executive to CEO of BCBS Louisiana

Tunde Sotunde, Anthem/Blue Medicaid leader to CEO of BCBS North Carolina

Board questions to ask (signal checks)

Where are we most exposed to external pulls in market presidents, actuarial, provider contracting, PBM strategy, MA growth, digital or AI, care management?

Do we have a three deep bench, internal and external, for all critical roles? What is our time to backfill?

What is the knowledge capture plan when a leader exits such as playbooks, contact maps, in flight deals, and risk registers?

Are we competitive on non cash glue such as mission equity, local impact, hybrid flexibility, board visibility, and innovation sandbox?

Are we importing enough new thinking from outside the Blues orbit to prevent stagnation?

10 mitigation moves (keep the upside, lower the risk)

Flight risk heatmap: score critical roles quarterly based on market demand, visibility, compensation gaps, recruiter activity.

Sticky compensation architecture: mission linked LTIPs, deferred awards, retention grants tied to regulatory or strategic milestones.

30 60 90 knowledge capture: mandated transition artifacts including provider and broker maps, pipeline, KPIs, dashboards, contacts.

Succession three deep: name internal number one and number two, plus external fast dial slates per critical role.

Talent treaties (opt in): targeted non solicit MOUs with neighboring Blues, structured with antitrust counsel, time bound, reciprocal.

Rotational fellowships (in system): formal secondments across Blues for skills transfer without permanent exit.

Interim playbooks: pre approved delegations, decision rights, and communications to shrink the dip.

Employer value proposition refresh: emphasize local mission, board access, innovation runway, and community impact.

Compensation competitiveness: counteroffers are never a good strategy and are often too little, too late. To avoid getting to that point, plans should frequently and comprehensively reassess how competitive their comp packages are. The top 5% of the organization, particularly the high performers, should feel confident that they're not "leaving money on the table".

Talent intelligence: monitor executive search signals, LinkedIn activity, and conference circuits; maintain warm networks.

Communications and optics

Members and providers: message continuity of strategy, name interim leaders, highlight bench depth.

Employees: transparent FAQs on why moves happen and how we backfill.

Regulators and policymakers: emphasize stability and consumer protections; share governance and risk controls.

Appendix A — Documented cross plan moves (sample)

Role and direction shown; dates reflect public announcements.

Brian D. Pieninck, CareFirst to GuideWell/Florida Blue, President & CEO (2025)

Sarah Iselin, Blue Shield of California to BCBS Massachusetts, President & CEO (2023)

Pat Geraghty, BCBS Minnesota to Florida Blue, President & CEO (2011); prior move Horizon BCBSNJ to BCBS Minnesota, SVP to CEO

David Corkum, CareFirst to BCBS Massachusetts, EVP Finance/Treasurer (2022)

Thurman Justice, Florida Blue/GuideWell to Triple S Management, President & CEO (2024)

Jessica Cox, Excellus BCBS to Highmark Health, SVP, Population & Health Quality Solutions (2023)

John Orner, BCBS Minnesota to Highmark Health, Enterprise CIO (2020)

Krishna Ramachandran, HCSC to Blue Shield of California, SVP, Health Transformation & Provider Adoption (2023)

Steven J. Krupinski, Capital Blue Cross to Horizon BCBSNJ, SVP, Market Business Units (2021)

Glenn McGrath, BCBS Illinois to Premera Blue Cross, SVP, Customer Experience (2018)

Kim Keck, BCBS Rhode Island CEO to President and CEO of Blue Cross Blue Shield Association (2021)

Martha L. Wofford, incoming CEO of BCBS Rhode Island, from DaVita and Aetna leadership (2021)

Gary D. St. Hilaire, Capital Blue Cross CEO to Horizon BCBS of New Jersey CEO (2020)

Bryan Camerlinck, Blue KC executive to CEO of BCBS Louisiana (2024)

Tunde Sotunde, Anthem/Blue Medicaid leader to CEO of BCBS North Carolina (2020)

Appendix B — Method and sources

Public announcements, plan newsrooms, and reputable industry trade coverage (2015 to 2025). Additional examples can be appended as we validate further moves across EVP/SVP/VP ranks.

If you'd like to schedule a complimentary consultation on how we've helped our client organizations implement effective succession planning strategies, please feel free to access my calendar here to book a call. 

© Steve McGovern and Executive Search Insights, 2025. Unauthorized use and/or duplication of this material without express and written permission is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to McGovern Executive Search with appropriate and specific direction to the original content.